目的 探讨金荞麦片联合复方异丙托溴铵治疗支气管哮喘的临床效果。方法 选取2017年5月—2018年5月在成都上锦南府医院就诊的支气管哮喘患者148例，根据用药差别进行分为对照组（74例）和治疗组（74例）。对照组患者雾化吸入吸入用复方异丙托溴铵溶液，2.5 mL/次，3次/d。治疗组在对照组基础上口服金荞麦片，4片/次，3次/d。两组患者连续治疗15 d。观察两组患者临床疗效，同时比较治疗前后两组患者症状积分、ACT评分、血清学指标和不良反应情况。结果 治疗后，对照组和治疗组总有效率分别为86.49%和97.30%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者症状积分显著降低（P<0.05），ACT评分显著升高（P<0.05），且治疗组症状积分和ACT评分明显好于对照组（P<0.05）。治疗后，两组患者白细胞介素-4（IL-4）、血清白细胞三烯B4（LTB4）和肿瘤坏死因子-α（TNF-α）水平均显著降低（P<0.05），且治疗组血清IL-4、LTB4和TNF-α水平明显低于对照组（P<0.05）。治疗期间，治疗组患者不良反应发生率为2.70%，显著低于对照组的13.51%，两组比较差异具有统计学意义（P<0.05）。结论 金荞麦片联合复方异丙托溴铵治疗支气管哮喘疗效显著、安全性高，且可显著改善患者体内炎症因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effects of Jinqiaomai Tablets combined with compound ipratropium bromide in treatment of bronchial asthma. Methods Patients (148 cases) with bronchial asthma in Chengdu Shangjin Nanfu Hospital from May 2017 to May 2018 were divided into control (74 cases) and treatment (74 cases) groups according to different treatments. Patients in the control group were atomization inhalation administered with Compound Ipratropium Bromide Solution for inhalation, 2.5 mL/time, three times daily. Patients in the treatment group were po administered with Jinqiaomai Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the symptom scores, ACT scores, the serological indicators levels and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 86.49% and 97.30% respectively, and there were differences between two groups (P<0.05). After treatment, the symptom scores in two groups were significantly decreased (P<0.05), but ACT scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum IL-4, LTB4 and TNF-α levels in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.70%, which was significantly lower than 13.51% in treatment the group, with significant difference between two groups (P<0.05). Conclusion Jinqiaomai Tablets combined with compound ipratropium bromide is effective and safe in treatment of bronchial asthma, and can significantly improve the level of inflammatory factors, which has a certain clinical application value.